EBITDA: Income before interest, taxes, depreciation and amortization.
Generate Biomedicines, Inc. (GENB) had EBITDA of -224.67M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
31.89M |
|
-249.52M |
|
-- |
|
31.89M |
|
266.96M |
|
-235.06M |
|
12.26M |
|
-222.80M |
|
-222.80M |
|
-222.97M |
|
-222.97M |
|
-222.97M |
|
-222.97M |
|
-235.06M |
|
|
EBITDA |
-224.67M |
32.98M |
|
32.98M |
|
-7.57 |
|
-7.57 |
|
| Balance Sheet Financials | |
234.37M |
|
29.15M |
|
95.82M |
|
330.18M |
|
82.20M |
|
2.91M |
|
863.94M |
|
946.15M |
|
-615.97M |
|
-615.97M |
|
-615.97M |
|
33.12M |
|
| Cash Flow Statement Financials | |
-200.62M |
|
116.77M |
|
28.06M |
|
181.83M |
|
126.04M |
|
-55.79M |
|
20.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.85 |
|
-- |
|
-- |
|
-0.00 |
|
-0.01 |
|
100.00% |
|
-737.04% |
|
-737.04% |
|
-704.45% |
|
-698.59% |
|
-782.38% |
|
-204.13M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
-- |
|
-- |
|
-- |
|
36.20% |
|
36.20% |
|
-67.53% |
|
36.37% |
|
-18.60 |
|
-6.19 |
|
-6.08 |
|